Isolated pulmonary Langerhans’ cell histiocytosis (LCH) is distinctly rare under the age of 15 years, since the majority of patients are young adult males with heavy smoking habits. Isolated pulmonary involvement suggests that antigens inhaled from cigarette smoke are involved. Here we present a case of LCH restricted to the lungs in a toddler whose parents were heavy smokers. Since LCH was not medically treated for 3 years due to parental refusal, the disease can be regarded as having followed its natural course. During the 3-year follow-up, the disease progressed to severe pulmonary fibrosis resulting in honeycomb lungs. Based on the comparative immunohistochemical analyses of the cells obtained from bronchoalveolar lavages during the disease course, it appears that the evolution of fibrosis is rather a result from the accumulating alveolar macrophages than from the persistence of the Langerhans’ cells. Passive cigarette smoking may be considered a significant risk factor in both the pathogenesis and development of pulmonary LCH in a small child.

Keywords:
Bronchoalveolar lavage, Immunohistochemistry, Langerhans’ cell histiocytosis, Maternal tobacco smoke, Pediatric histiocytosis
1.
Favara BE, Feller AC, Pauli M, et al: Contemporary classification of histiocytic disorders. Med Pediatr Oncol 1997;29:157–166.
2.
Nicholson HS, Egeler RM, Nesbit ME: The epidemiology of Langerhans cell histiocytosis. Hematol Oncol Clin North Am 1998;12:379–384.
3.
Berlow ME, Markarian B, Heitzman ER, Raasch BN: Diffuse pulmonary disease in a 2 1/2-year-old child. JAMA 1982;248:875–876.
4.
Schulze J, Kitz R, Gruttner HP, Schmidt H, Zielen S: Severe isolated pulmonary Langerhans cell histiocytosis in a 6-year-old girl. Eur J Pediatr 2004;163:320–322.
5.
Delobbe A, Durieu J, Duhamel A, Wallaert B: Determinants of survival in pulmonary Langerhans’ cell granulomatosis (histiocytosis X). Eur Respir J 1996;9:2002–2006.
6.
Tazi A, Soler P, Hance AJ: Adult pulmonary Langerhans’ cell histiocytosis. Thorax 2000;55:405–416.
7.
Selman M: The spectrum of smoking-related interstitial lung disorders: Chest 2003;124:1185–1187.
8.
Zeid NA, Muller HK: Tobacco smoke induced lung granulomas and tumors: association with pulmonary Langerhans cells. Pathology 1995;27:247–254.
9.
Travis WD, Borok Z, Roum JH, et al: Pulmonary Langerhans cell granulomatosis (histiocytosis X): a clinicopathologic study of 48 cases. Am J Surg Pathol 1993;17:971–986.
10.
Vassallo R, Ryu JH, Colby TV, Hartman T, Limper AH: Pulmonary Langerhans’ cell histiocytosis. N Engl J Med 2000;342:1969–1978.
11.
Tasi A, Bonay M, Grandsaigne M, Battesti JP, Hance AJ, Soler P: Surface phenotype of Langerhans cells and lymphocytes in granulomatous lesions from patients with pulmonary histiocytosis X. Am Rev Respir Dis 1993;147:1531–1536.
12.
Nagy B, Katona É, Erdei J, et al: Fibronectin in bronchoalveolar lavage fluid and plasma from children with chronic inflammation of lungs. Acta Paediatr Scand 1988;77:727–733.
13.
Diette GB, Scatarige JC, Haponik EF, Merriman B, Fishman EK: Do high-resolution CT findings of usual interstitial pneumonitis obviate lung biopsy? Views of pulmonologists. Respiration 2005;72:134–141.
14.
McLelland J, Broadbent V, Yeomans E, Malone M, Pritchard J: Langerhans cell histiocytosis: the case for conservative treatment. Arch Dis Child 1990;65:301–303.
15.
Gadner H, Grois N, Arico M, et al: Histiocyte society. A randomised trial of treatment for multisystem Langerhans’ cell histiocytosis. J Pediatr 2001;138:728–734.
16.
Dezső B, Haas GP, Hamzavi F, et al: The mechanism of local tumor irradiation combined with interleukin 2 therapy in murine renal carcinoma: histological evaluation of pulmonary metastases. Clin Cancer Res 1996;2:1543–1552.
17.
Rehli M, Krause SW, Andreesen R: The membrane-bound ectopeptidase CPM as a marker of macrophage maturation in vitro and in vivo. Adv Exp Med Biol 2000;477:205–216.
18.
Nondahl SR, Finlay JL, Farrel PM, Warner TF, Hong R: A case report and literature review of ‘primary’ pulmonary histiocytosis X of childhood. Med Pediatr Oncol 1986;14:57–62.
19.
Laman JD, Leenen PJ, Annels NE, Hogendoorn PC, Egeler RM: Langerhans-cell histiocytosis ‘insight into DC biology’. Trends Immunol 2003;24:409–410.
20.
Murakami I, Gogusev J, Fournet JC, Glorion C, Jaubert F: Detection of molecular cytogenetic aberrations in Langerhans cell histiocytosis of bone. Hum Pathol 2002;33:555–560.
21.
Vassallo P, Jensen A, Colby TV, et al: The overlap between respiratory bronchiolitis and desquamative interstitial pneumonia in pulmonary Langerhans cell histiocytosis. High-resolution CT, histologic, and functional correlations. Chest 2003;124:1199–1205.
22.
Youkeles LH, Grizzanti JN, Liao Z, Chang CJ, Rosenstreich DL: Decreased tobacco-glycoprotein-induced lymphocyte proliferation in vitro in pulmonary eosinophilic granuloma. Am J Respir Crit Care Med 1995;151:145–150.
23.
Kambouchner M, Basset F, Marchal J, Uhl JF, Hance AJ, Soler P: Three-dimensional characterization of pathologic lesions in pulmonary Langerhans cell histiocytosis. Am J Respir Crit Care Med 2002;166:1483–1490.
24.
Vassallo R, Ryu JH, Schroeder DR, Decker PA, Limper AH: Clinical outcomes of pulmonary Langerhans’-cell histiocytosis in adults. N Engl J Med 2002;346:484–490.
25.
Ryu JH, Colby TV, Hartman TE, Vassallo R: Smoking-related interstitial lung diseases: a concise review. Eur Respr J 2001;17:122–132.
26.
Sundar KM, Gosselin MV, Chung HL, Cahill BC: Pulmonary Langerhans cell histiocytosis. Emerging concepts in pathobiology, and clinical evolution of disease. Chest 2003;123:1673–1683.
27.
Paciocco G, Uslenghi E, Mazzarella G, Roviaro GC, Vecchi G, Harari S: Diffuse cystic lung diseases. Correlation between radiologic and functional status. Chest 2004;125:135–142.
28.
McClain KL, Gonzalez JM, Jonkers R, De Juli E, Egeler M: Need for a cooperative study: pulmonary Langerhans cell histiocytosis and its management in adults. Med Pediatr Oncol 2002;39:35–39.
© 2006 S. Karger AG, Basel
2005
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.